Plain-English translation of NCT07144228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Duke University are testing a new blood test called HeLP™ that looks at proteins on platelets (tiny blood cells) to detect prostate cancer. Instead of relying on multiple tests like PSA blood tests, MRI scans, and biopsies, this single blood draw might give doctors a faster, simpler way to diagnose prostate cancer and understand how serious it is.
Currently, doctors use several different tests to diagnose prostate cancer, which can be time-consuming and inconvenient for patients. This new treatment aims to provide a single, accurate blood test that could replace or reduce the need for these multiple tests.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll visit Duke Health for your routine prostate cancer evaluation (PSA test or imaging). At that same visit, the research team will collect three extra tubes of blood—about 3 tablespoons total—which takes just a few minutes. The study includes an interim check halfway through (after 150 participants), and researchers will compare your results with others to see how accurate the new blood test is.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Collaborators
Hessian Labs Inc
Enrollment target
~300 participants
Started
March 2026
Primary completion
September 2026
Age range
40 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Judd Moul, MD
Duke University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.